Total Funding
45
49
Total FundingVenture - Series Unknown raised
Growth Score
-7 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
84495
PellePharm develops patidegib, a novel hedgehog pathway inhibitor to mitigate the tumor burden in patients with basal cell carcinomas.
- Sanuj Ravindran: CEO
Joseph Suttner: Vice President, Clinical OperationsPast Role: Aimmune Therapeutics, VP Clinical Operations
About the Company
PellePharm develops patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of
life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them.
Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in phase 2 clinical trial for the treatment of sporadic BCCs.
